EcoDrugPlus

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSCPOG00000001458
Gene Symbol: PSMB6
4 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSCPOG00000007839
Gene Symbol: PSMB7
2 Cross references
218 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSCPOG00000000729
Gene Symbol: PSMB8
2 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 9

Ensembl ID : ENSCPOG00000002121
Gene Symbol: PSMB9
2 Cross references
214 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSCPOG00000009183
Gene Symbol: PSMD2
2 Cross references
224 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4

Ensembl ID : ENSCPOG00000033777
Gene Symbol: PSMD4
4 Cross references
293 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSCPOG00000002424
Gene Symbol: PSMC1
4 Cross references
308 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSCPOG00000027107
Gene Symbol: PSMC2
2 Cross references
229 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSCPOG00000008176
Gene Symbol: PSMC3
2 Cross references
228 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSCPOG00000003943
Gene Symbol: PSMC4
2 Cross references
199 Possible Orthologues:

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSCPOG00000011376
Gene Symbol: PSMC5
4 Cross references
226 Possible Orthologues:

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSCPOG00000009477
Gene Symbol: PSMC6
4 Cross references
239 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).